AA
CLPT icon

AlphaCentric Advisors’s ClearPoint Neuro CLPT Stock Holding History

AlphaCentric Advisors’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$561K Sell
50,000
-7,500
-13% -$112K 0.16% 59
2021
Q3 		$1.02M Buy
57,500
+7,500
+15% +$141K 0.26% 28
2021
Q2 		$955K Hold
50,000
– – 0.26% 27
2021
Q1 		$1.06M Buy
+50,000
New +$1.07M 0.36% 23

Other funds holding CLPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
GPC
Guardian Point Capital Charlottesville, Virginia $243M AUM 22.43% 1-Year Est. Return

AlphaCentric Advisors's CLPT Position: Q4 2021 in Review

AlphaCentric Advisors reduced its ClearPoint Neuro (CLPT) stake by 13% in Q4 2021, selling an estimated $112K and leaving 50,000 shares worth $561K. The position accounts for 0.16% of the portfolio, ranked #59.

AlphaCentric Advisors first reported a position in CLPT in Q1 2021 and has held it in 4 quarters since. The position peaked at $1.06M in Q1 2021. 67 funds tracked by Wall St. Rank hold CLPT as of Q4 2021.

  • AlphaCentric Advisors held 50,000 shares of ClearPoint Neuro worth $561K as of Q4 2021.
  • AlphaCentric Advisors sold 7,500 ClearPoint Neuro shares in Q4 2021, an estimated $112K.
  • ClearPoint Neuro made up 0.16% of AlphaCentric Advisors's portfolio in Q4 2021, its #59 holding.
  • AlphaCentric Advisors first reported a position in ClearPoint Neuro in Q1 2021 and has held it in 4 quarters since.
  • AlphaCentric Advisors's ClearPoint Neuro position peaked at $1.06M in Q1 2021.
  • 67 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.